Signaturefd, LLC Prothena Corp Public LTD CO Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Signaturefd, LLC holds 901 shares of PRTA stock, worth $13,154. This represents 0.0% of its overall portfolio holdings.

Number of Shares

901

Previous 1,337 32.61%

Holding current value

$13,154

Previous $27,000 44.44%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$16.73 - $24.79 $7,294 - $10,808	-436 Reduced 32.61%	901 $15,000
Q2 2024 Jul 29, 2024	BUY	$19.54 - $26.15 $16,863 - $22,567	863 Added 182.07%	1,337 $27,000
Q1 2024 May 03, 2024	BUY	$24.75 - $40.66 $2,400 - $3,944	97 Added 25.73%	474 $11,000
Q4 2023 Jan 31, 2024	BUY	$32.31 - $52.32 $2,649 - $4,290	82 Added 27.8%	377 $13,000
Q3 2023 Nov 03, 2023	SELL	$47.3 - $70.6 $283 - $423	-6 Reduced 1.99%	295 $14,000
Q2 2023 Aug 01, 2023	BUY	$48.26 - $78.59 $289 - $471	6 Added 2.03%	301 $20,000
Q1 2023 Apr 28, 2023	SELL	$46.97 - $58.27 $2,113 - $2,622	-45 Reduced 13.24%	295 $14,000
Q4 2022 Jan 27, 2023	SELL	$52.05 - $65.0 $4,372 - $5,460	-84 Reduced 19.81%	340 $20,000
Q3 2022 Nov 08, 2022	BUY	$25.16 - $60.63 $100 - $242	4 Added 0.95%	424 $26,000
Q3 2021 Oct 28, 2021	SELL	$48.2 - $78.89 $10,025 - $16,409	-208 Reduced 33.12%	420 $30,000
Q2 2021 Jul 26, 2021	SELL	$21.63 - $57.65 $821 - $2,190	-38 Reduced 5.71%	628 $32,000
Q1 2021 Apr 30, 2021	BUY	$11.0 - $28.24 $451 - $1,157	41 Added 6.56%	666 $17,000
Q2 2020 Jul 30, 2020	BUY	$9.56 - $12.51 $5,975 - $7,818	625 New	625 $7,000
Q3 2019 Oct 16, 2019	SELL	$6.89 - $10.45 $27 - $41	-4 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$27.95 - $45.04 $111 - $180	4 New	4 $0

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account